{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:39:40Z","timestamp":1792449580039,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22367006"],"award-info":[{"award-number":["22367006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903472"],"award-info":[{"award-number":["81903472"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bioorg.2025.109229","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T01:24:23Z","timestamp":1763083463000},"page":"109229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Identification of 2,4-disubstitued pyridine derivatives as potent FMS-like tyrosine receptor kinase 3 (FLT3) inhibitors"],"prefix":"10.1016","volume":"167","author":[{"given":"Zhongyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youli","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weike","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2025.109229_bb0005","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood-2024-208967","article-title":"The burden of Leukemia in the United States from 1990 to 2021","volume":"144","author":"Saadeh","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bioorg.2025.109229_bb0010","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/j.clml.2025.03.006","article-title":"Analyzing Two Decades of Leukemia Mortality in the U.S. (1999\u20132020)","volume":"25","author":"Aziz","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.bioorg.2025.109229_bb0015","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.109229_bb0020","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109229_bb0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bioorg.2025.109229_bb0030","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109229_bb0035","first-page":"124","article-title":"Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study","volume":"10","author":"Brandwein","year":"2020","journal-title":"Am J Blood Res."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109229_bb0040","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bioorg.2025.109229_bb0045","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.25620","article-title":"Maintenance therapy in AML: the past, the present and the future","volume":"94","author":"Molica","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"291","key":"10.1016\/j.bioorg.2025.109229_bb0050","doi-asserted-by":"crossref","first-page":"291ra96","DOI":"10.1126\/scitranslmed.aaa5731","article-title":"Integration of hedgehog and mutant FLT3 signaling in myeloid leukemia","volume":"7","author":"Lim","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109229_bb0055","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2025.109229_bb0060","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","article-title":"FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML","volume":"115","author":"Pratz","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bioorg.2025.109229_bb0065","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"issue":"24","key":"10.1016\/j.bioorg.2025.109229_bb0070","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1111\/jcmm.17608","article-title":"Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia","volume":"26","author":"Jensen","year":"2022","journal-title":"J. Cell. Mol. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109229_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104367","article-title":"Targeting FLT3 for treating diseases: FLT3 inhibitors","volume":"30","author":"Rong","year":"2025","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.bioorg.2025.109229_bb0080","first-page":"961","article-title":"Recent advances in FLT3 inhibitors for acute myeloid leukemia, future","volume":"12","author":"Tong","year":"2020","journal-title":"Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2025.109229_bb0085","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.3390\/ijms25179448","article-title":"Enhancing therapeutic efficacy of FLT3 inhibitors with combination therapy for treatment of acute myeloid Leukemia","volume":"25","author":"Leifheit","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.bioorg.2025.109229_bb0090","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.bioorg.2025.109229_bb0095","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and Gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109229_bb0100","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/17512433.2017.1387051","article-title":"Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis","volume":"10","author":"Kayser","year":"2017","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"17","key":"10.1016\/j.bioorg.2025.109229_bb0105","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/14656566.2020.1801637","article-title":"Quizartinib for the treatment of acute myeloid leukemia","volume":"21","author":"Garcia-Horton","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"issue":"21","key":"10.1016\/j.bioorg.2025.109229_bb0110","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bioorg.2025.109229_bb0115","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3390\/ijms19103198","article-title":"Targeting oncogenic Signaling in mutant FLT3 acute myeloid Leukemia: the path to least resistance","volume":"19","author":"Staudt","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2025.109229_bb0120","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.cellsig.2009.06.002","article-title":"Oncogenic signaling from the hematopoietic growth factor receptors c-kit and Flt3","volume":"21","author":"Masson","year":"2009","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109229_bb0125","first-page":"36","article-title":"Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia","volume":"7","author":"Kim","year":"2021","journal-title":"Cardiooncology"},{"issue":"19","key":"10.1016\/j.bioorg.2025.109229_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126630","article-title":"Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"29","author":"Xu","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109229_bb0135","doi-asserted-by":"crossref","unstructured":"B.J. Chen, Z.Y. Wang, Q. Chen, Y. Zhang, S.F. Wu, Y. Zhang, A.H. Li, W.W. Ouyang, LJ. Sima, X.X. Li, D.S. Zhao, B.L. Luo, J.T. Wang, L. Tang, X.M. Su, W.K. Liao, Discovery of pyridine-based derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia, Eur. J. Med. Chem. 283 (2025) 117173. doi:https:\/\/doi.org\/10.1016\/j.ejmech.2024.117173.","DOI":"10.1016\/j.ejmech.2024.117173"},{"key":"10.1016\/j.bioorg.2025.109229_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112244","article-title":"Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-met kinase inhibitors","volume":"194","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.109229_bb0145","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1080\/10426500903348013","article-title":"Reactions with hydrazonoyl halides 63: synthesis and anticancer activity of some new 1,3,4-thiadiazoles, 1,3,4-selenadiazoles, and 1,2,4-triazolo[4,3-a]pyrimidines","volume":"185","author":"Abdelall","year":"2010","journal-title":"Phosphorus Sulfur Silicon Relat. Elem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.109229_bb0150","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.bmc.2019.03.049","article-title":"Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2","volume":"27","author":"Qi","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109229_bb0155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejphar.2019.03.041","article-title":"CS2164 suppresses acute myeloid leukemia cell growth via inhibiting VEGFR2 signaling in preclinical models","volume":"853","author":"Deng","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109229_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105591","volume":"120","author":"Abdelall","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109229_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2025.09.010","article-title":"Computation-driven discovery of novel chromone derivatives for the treatment of triple-negative breast cancer via mTOR-targeted inhibition and triggering antitumor immunity","author":"Zhang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.109229_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117492","article-title":"Design, synthesis, and biological evaluation of pyridine-based derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia","volume":"289","author":"Wu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109229_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112309","article-title":"Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3K\u03b1 inhibitors with potent antitumor activity","volume":"197","author":"Liao","year":"2020","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:59:18Z","timestamp":1777463958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825011095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"alternative-id":["S0045206825011095"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109229","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of 2,4-disubstitued pyridine derivatives as potent FMS-like tyrosine receptor kinase 3 (FLT3) inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109229"}}